Attention-Deficit Hyperactivity Disorder (ADHD) Clinical Trial
Official title:
Phase II, Open-label, Dose-titration, Safety Study Designed to Determine the Evening Dose of a Novel Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) to Produce Optimal Clinical Effects in Children With ADHD
The phase 2 study will evaluate the safety, tolerability and efficacy of HLD100 at steady state (following up to 5 weeks of treatment) in children using an outpatient, single-center, open-label, flexible dose-escalation study design.
This dose-escalation study will examine HLD100 in 24 subjects. The subjects (n=24) will be tested with HLD100 in ascending doses from 10mg up to 40mg. This study will be divided into several phases: Screening, Active Treatment and Follow-Up. All visits have a 2 day window to allow for scheduling. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01430767 -
Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder
|
N/A | |
| Completed |
NCT03231800 -
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
|
Phase 3 | |
| Completed |
NCT02286817 -
Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
|
Phase 1 | |
| Completed |
NCT02699086 -
A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)
|
Phase 2 | |
| Suspended |
NCT05202327 -
PDC-1421 Treatment in Adult Patients With ADHD
|
Phase 2 | |
| Completed |
NCT02734693 -
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
|
Phase 3 |